The non-coding genome, once dismissed as "junk DNA", is now recognized as a fundamental regulator of gene expression and a key player in understanding complex diseases. Following the landmark achievements of the Human Genome Project (HGP), scientists have increasingly focused on deciphering the non-coding regions of the human genome, which comprise approximately 98% of the genetic material. These regions, long overlooked due to their non-protein-coding nature, are now known to harbor regulatory elements crucial for cell function and disease progression.

Prostate cancer remains a global health challenge, ranking as the second most common malignancy among men. While early-stage disease can be effectively managed, advanced forms—particularly metastatic castration-resistant prostate cancer (mCRPC)—pose significant therapeutic hurdles. A growing body of evidence highlights the pivotal role of SOX transcription factors, with SOX2 emerging as a central driver in tumor growth, spread, and resistance to therapy.

A University of Massachusetts Amherst kinesiologist has received a five-year, $2 million grant from the National Institutes of Health (NIH) to advance his research on how myosin molecules—molecular motors crucial for muscle contraction— work together to drive different processes within cells.

A new study suggests that a DNA-damaging gut bacterium may drive cancer development in patients with familial adenomatous polyposis (FAP), a rare inherited condition that causes hundreds of colon polyps and almost always leads to colorectal cancer if untreated.